HomeCompareGKPRF vs ABBV

GKPRF vs ABBV: Dividend Comparison 2026

GKPRF yields 232.29% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GKPRF wins by $291.48M in total portfolio value
10 years
GKPRF
GKPRF
● Live price
232.29%
Share price
$0.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$291.58M
Annual income
$157,877,990.68
Full GKPRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GKPRF vs ABBV

📍 GKPRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGKPRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GKPRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GKPRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GKPRF
Annual income on $10K today (after 15% tax)
$19,744.48/yr
After 10yr DRIP, annual income (after tax)
$134,196,292.08/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GKPRF beats the other by $134,175,236.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GKPRF + ABBV for your $10,000?

GKPRF: 50%ABBV: 50%
100% ABBV50/50100% GKPRF
Portfolio after 10yr
$145.84M
Annual income
$78,951,381.22/yr
Blended yield
54.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GKPRF
No analyst data
Altman Z
18.5
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GKPRF buys
0
ABBV buys
0
No recent congressional trades found for GKPRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGKPRFABBV
Forward yield232.29%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$291.58M$102.3K
Annual income after 10y$157,877,990.68$24,771.77
Total dividends collected$276.92M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GKPRF vs ABBV ($10,000, DRIP)

YearGKPRF PortfolioGKPRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$33,929$23,228.80$11,550$430.00+$22.4KGKPRF
2$109,960$73,656.59$13,472$627.96+$96.5KGKPRF
3$340,756$223,097.98$15,906$926.08+$324.9KGKPRF
4$1,010,736$646,127.97$19,071$1,382.55+$991.7KGKPRF
5$2,872,629$1,791,140.59$23,302$2,095.81+$2.85MGKPRF
6$7,831,307$4,757,594.68$29,150$3,237.93+$7.80MGKPRF
7$20,501,057$12,121,558.03$37,536$5,121.41+$20.46MGKPRF
8$51,592,409$29,656,278.45$50,079$8,338.38+$51.54MGKPRF
9$124,953,592$69,749,714.13$69,753$14,065.80+$124.88MGKPRF
10$291,578,334$157,877,990.68$102,337$24,771.77+$291.48MGKPRF

GKPRF vs ABBV: Complete Analysis 2026

GKPRFStock

Gatekeeper Systems Inc. designs, manufactures, markets, and sells video security solutions for mobile and extreme environments in Canada and the United States. Its mobile video solutions integrate high-definition digital video with the global positioning system (GPS) for real-time vehicle location, time, date, and telematics data; and provide a 360-degree view inside and outside vehicles. The company's wireless devices provide real-time connectivity, streaming video, and vehicle tracking; video management software is used as a desktop application for managing basic incidents; and enterprise software to stream live video from any vehicle. It also offers platform-as-a-service to enable intelligent transportation systems for smart city initiatives. The company's products include interior and exterior cameras, DVR recorders, and dashboard cameras; G4 Vision that enables finding video, clipping and saving incidents, and sharing of data; G4 Viewer Plus Incident Management Software that synchronizes GPS, video, vehicle sensors, voice, and other metadata allowing end users to share incidents with management or law enforcement; and wireless systems, such as health check, access point, mobile wireless, mobile WIFI, and video capture and storage modules. In addition, it provides traffic infraction management software, a web based portal that provides functionality for the public who have received a stop arm violation citation/ticket and for internal staff, to document, review, and track the status of alleged stop arm infraction; and intelligent temperature sensing system, a health monitoring panel that measures the body temperature of individuals entering a transportation vehicle or building. The company serves the transit, rail, school bus, police, ambulance, taxi, and transport markets. Gatekeeper Systems Inc. was founded in 1997 and is headquartered in Abbotsford, Canada.

Full GKPRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GKPRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GKPRF vs SCHDGKPRF vs JEPIGKPRF vs OGKPRF vs KOGKPRF vs MAINGKPRF vs JNJGKPRF vs MRKGKPRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.